Bevacizumab induces normalization of abnormal blood vessels, making them less leaky. By binding to vascular endothelial growth factor, it indirectly attacks the vascular tumor mass. The optimal delivery of targeted therapies including monoclonal antibodies or anti-angiogenesis drugs to the target tissue highly depends on the blood-brain barrier permeability. It is therefore critical to investigate how drugs effectively reach the tumor. In situ investigation of drug distribution could provide a better understanding of pharmacological agent action and optimize chemotherapies for solid tumors. We developed an imaging method coupled to protein identification using matrix-assisted laser desorption/ionization mass spectrometry. This approach monitored bevacizumab distribution within the brain structures, and especially within the tumor, without any labeling.

贝伐单抗可诱导异常血管正常化，从而减少渗漏。通过与血管内皮生长因子结合，它间接攻击血管肿瘤块。靶向治疗药物（包括单克隆抗体或抗血管生成药物）向靶组织的最佳输送高度取决于血脑屏障通透性。因此，至关重要的是研究药物如何有效地到达肿瘤。药物分布的原位调查可以更好地了解药理作用并优化实体瘤的化学疗法。我们开发了一种成像方法，结合使用基质辅助激光解吸/电离质谱法进行蛋白质鉴定。这种方法可以监测贝伐单抗在大脑结构内，尤其是在肿瘤内的分布，